2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Serologic Tests, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4078 Ex vivo drug sensitivity as a biomarker of prognosis and candidate agents for resistant multiple myeloma

Arwa Bohra, MD, Joachim L. Petit2, Kelli Ann Gyotoku3, Matthew Smith4, Wilson Gonsalves, MD5, P. Leif Bergsagel, MD6, Shaji Kumar, MD7
1 Mayo Clinic, Rochester, United States
2 Mayo Clinic, Jacksonville, United States
3 Mayo Clinic, Rochester, United States
4 Mayo Clinic, Rochester, United States
5 Mayo Clinic, Rochester, United States
6 Mayo Clinic, Arizona, United States
7 Mayo Clinic, Rochester, United States

Background
Functional drug testing can capture therapeutic vulnerabilities not apparent from genomic profiling alone, offering a path toward precision medicine in guiding therapy selection.

Methods

We performed same-day ex vivo drug-sensitivity testing on freshly obtained CD138+ myeloma cells using the previously described “Direct-to-Drug” platform (Bonolo de Campos et al., 2020), with 24-hour CellTiter-Glo viability assessment across 7-point drug dilutions. Drug response was summarized using normalized AUC, with lower AUC indicating greater sensitivity, and measured OS from sampling to death or last follow-up using one observation per patient. Drug AUCs were used to predict survival kinetics and optimal thresholds were obtained for drugs with impact on survival. Corresponding RNA-sequencing data were also analyzed. (n=12).

Results
Among 169 MM encounters from 158 unique patients, 110 (65.1%) were previously treated and 59 (34.9%) were treatment-naive. Median follow-up from testing was 57.7 mo, 63.4 mo for NDMM and 50.6 mo for treated MM. Overall, 96 drugs were tested, with a median of 82 per encounter. The lowest median AUC values overall (<0.2) were observed for PMX-464 (thioredoxin (Trx1)/thioredoxin reductase (TrxR1) system inhibitor), S63845 (MCL1 inhibitor), auranofin, carfilzomib, and JWT-001. Among treatment-exposed encounters, AUC <0.2 was most frequent for PMX-464 (87.7%), auranofin (86.0%), S63845 (81.8%), AMG-176 (MCL-1 inhibitor) (60.6%), carfilzomib (59.1%), YM-155 (survivin inhibitor) (51.5%), bortezomib (44.9%), JWT-001 (41.2%), and dinaciclib (40.8%).

Among treatment-naive patients, each 0.1-unit increase in AUC was associated with inferior OS, with the hazard ratio (HR) highest for lenalidomide (2.7; 95% CI, 1.1–6.8; P<0.05), followed by ixazomib (2.5; 1.5–4.2; p<0.01), bortezomib (2.2; 1.4–3.4; p<0.01), and carfilzomib (1.7; 1.2–2.5; p<0.01). At an AUC cutoff of 0.2, carfilzomib sensitivity predicted superior OS (0.1; 0.0–0.6; p<0.05), while venetoclax sensitivity showed a nonsignificant favorable trend (0.2; 0.1–1.2; p=0.08) suggesting specific use cases. Maximally selected cutoffs further identified resistant subgroups with inferior OS: for bortezomib, AUC >0.3 was associated with median OS of 60.7 months versus not reached (M=4.7; p<0.01); for carfilzomib, AUC >0.2 was associated with median OS of 72.5 mo versus not reached (M=3.3). For lenalidomide, AUC ≥0.8 was associated with median OS of 95.5 mo versus not reached (9.2; 1.1–75.7; p<0.05, max-adjusted=0.3).

Alternative ex-vivo activity remained evident within resistant subgroups. Among carfilzomib-resistant cases, PMX-464 and auranofin each had AUC <0.2 in 57.1%; among bortezomib-resistant cases, both were sensitive in 61.9%. In lenalidomide-resistant MM, AUC <0.2 was observed for auranofin (83.7%), PMX-464 (81.6%), S63845 (79.4%), carfilzomib (55.3%), AMG-176 (50%), and bortezomib (48%). Similarly, venetoclax-resistant cases retained sensitivity to auranofin (83%), PMX-464 (78.7%), S63845 (71.4%), carfilzomib (55.4%), and JWT-001 (50%).

Hierarchical clustering of ex vivo drug-sensitivity profiles (130 of 169 encounters meeting ≥70% AUC completeness) identified two clusters in both exposed and non-exposed. Among treatment-naive patients, Cluster 1 (n=7) trended towards better outcomes (95% CI, NR–NR, 7 events), vs Cluster 2 (n=39) median OS also not reached (95.5–NR mo; P=0.3, 7 events). In this treatment-naive setting, both clusters showed sensitivity (median AUC <0.20) to carfilzomib and venetoclax, with Cluster 1 additionally sensitive to dinaciclib, bortezomib, and panobinostat, Cluster 2 additionally sensitive to auranofin, PMX-464, S63845, and JWT-001. Among treatment-exposed patients, Cluster 1 (n=38) had a significantly shorter median OS of 17.9 months (7.5–36.6) compared to Cluster 2 (n=35), which had a median OS of 44.1 months (P=0.04). In the treatment-exposed setting, both clusters shared sensitivity to carfilzomib, S63845, PMX-464, and auranofin, while Cluster 1 was uniquely sensitive to dinaciclib, AMG-176, YM-155, and JWT-001.

Conclusion
This is proof of concept that ex vivo sensitivities to various drugs correlate with survival and could inform therapy selection and adaptive clinical trial design. Auranofin and PMX-464 induced ≥90% killing (AUC ≤0.1) in a significant proportion of samples, marking them as strong candidates for clinical trials.

Arwa Bohra, MD: No relevant conflicts of interest to declare.